This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Eiden, J J
Right arrow Articles by Taylor, J L
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Eiden, J J
Right arrow Articles by Taylor, J L

 Previous Article  |  Next Article 

J Clin Microbiol. 1994 June; 32(6): 1599-1603

Serum antibody response to recombinant major inner capsid protein following human infection with group B rotavirus.

J J Eiden, A Mouzinho, D A Lindsay, R I Glass, Z Y Fang and J L Taylor

Department of Pediatrics, Johns Hopkins, University School of Medicine, Baltimore, Maryland 21205.

ABSTRACT

Recombinant major inner capsid protein (VP6) of the IDIR strain of group B rotavirus (GBR) was incorporated in a solid-phase immunoassay to access antibody response to infection in humans. Expression of VP6 in insect cells permitted design of a highly sensitive assay that avoided the contaminants present in GBR antigens obtained from fecal specimens. Among patients infected with the ADRV strain of GBR in China, increased reactivity with recombinant VP6 was observed in convalescent-phase sera in comparison with sera obtained shortly after infection (P = 0.0084). Anti-VP6 antibodies were detectable as soon as 7 days after onset of gastrointestinal symptoms, and serum reactivity persisted in specimens drawn more than 1 year after infection. Solid-phase immunoassay with recombinant VP6 was next employed in order to assess anti-GBR antibody in 513 serum specimens obtained from 423 Maryland residents (ages, 7 months to 96 years; median age, 42 years). Four individuals (< 1%) exhibited serum antibodies directed against the recombinant VP6 (ages, 54 to 95 years; mean age, 77 years). Examination of 129 additional serum specimens including some from other geographic regions of the United States failed to reveal the presence of anti-GBR antibody. Anti-GBR antibody was also not detected in any of 131 serum specimens from 60 staff and residents of a nursing home in Switzerland. While infection of humans with GBR has been uncommon in these locations outside of China, the detection of serum antibodies in older individuals in the United States either indicated an unknown, age-related risk factor or may have indicated infection in the more distant past. The availability of these reagents should allow surveys for GBR infection among additional populations that have not previously been investigated.


J Clin Microbiol. 1994 June; 32(6): 1599-1603




This article has been cited by other articles:

  • Tsunemitsu, H., Kamiyama, M., Kawashima, K., Katsuda, K., Kohmoto, M., Saif, L. J., Shouji, T., Onodera, T. (2005). Molecular characterization of the major capsid protein VP6 of bovine group B rotavirus and its use in seroepidemiology. J. Gen. Virol. 86: 2569-2575 [Abstract] [Full Text]